Fig. 1.

Schematic representation of the design of trastuzumab IgE antibody. To engineer trastuzumab IgE, the variable heavy and light chains of trastuzumab (IgG1, left; regions indicated with stars) were inserted into the epsilon heavy chain regions of IgE and the epsilon heavy chain was combined with the kappa light chain to produce the corresponding trastuzumab IgE antibody (right). The resulting engineered IgE molecule should recognise the HER2/neu antigen and IgE receptors (see Supplementary Table I, Supplementary Data for full sequence). Glycosylation sites are depicted by black circles